Medivation's Dimebon improves cognitive function in Huntington's disease
This article was originally published in Scrip
Executive Summary
Medivation's investigational drug Dimebon, whose most advanced indication is Alzheimer's disease, improves cognitive function in patients with Huntington's disease and is safe and well-tolerated, top-line results from a Phase II trial suggest.